Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment


A Phase I, Open-Label Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety Profile of CC-4047 in Subjects With Advanced Solid Tumors


CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor.


This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment.

Study Status: Completed


Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific Drug: CC-4047 Phase 1

Verified by Case Comprehensive Cancer Center August, 2012

Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center identifier: NCT00482521

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States

Matthew M. Cooney, MD., Study Chair
Robert Dreicer, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site